Trials / Not Yet Recruiting
Not Yet RecruitingNCT07047443
SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression
Dose Exploration Study of SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Anhui Provincial Cancer Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To find the optimal dose of carboplatin combined with SHR-A1811 in her2-expressed metastatic breast cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR- A1811 | HER2 ADC |
Timeline
- Start date
- 2025-08-01
- Primary completion
- 2027-12-31
- Completion
- 2029-12-31
- First posted
- 2025-07-02
- Last updated
- 2025-07-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07047443. Inclusion in this directory is not an endorsement.